601A anti-VEGF Ab is under clinical development by Sunshine Guojian Pharmaceutical Shanghai and currently in Phase III for Branch Retinal Vein Occlusion. According to GlobalData, Phase III drugs for ...

Frosted branch angiitis is a rare condition that makes the blood vessels that supply the retina look like the frosted ...

QUASAR is a global, double-masked, active-controlled phase 3 trial evaluating the efficacy and safety of EYLEA HD, compared to EYLEA, in patients with retinal vein occlusion (RVO), including those ...

korea.ac.kr Background/aims To identify risk factors of recurrence of macular oedema in branch retinal vein occlusion (BRVO) after intravitreal bevacizumab (IVB) injection. Methods The records of 63 ...

Regeneron Pharmaceuticals REGN announced that it has met the primary endpoint in a late-stage study evaluating Eylea HD ...

These elevated pressures can extend to ocular veins, resulting in complications such as central retinal vein occlusion (CRVO). This case report highlights a rare instance of CRVO combined with ...

R. China Ablation Experiments,Age-related Macular Degeneration,Aggregation Parameter,Amount Of Images,Average Accuracy,Branch Retinal Vein Occlusion,Central Retinal Vein Occlusion,Communication Rounds ...

The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help shore up sales of their Eylea franchise amid biosimilar encroachment. The ...

In a recent study, the company and its partner Bayer compared Eylea HD to the original version of Eylea in patients with macular edema following retinal vein occlusion (RVO), a common cause of ...

The dilemma still holds regarding treatment of the very ischemic central retinal vein occlusion subgroup with ME with profound visual loss. Combination therapy of anti-VEGF agents and a steroid ...